Cereno Scientific announces appointment of Dr. Raymond L. Benza to the Scientific Advisory Board

Cereno Scientific today announced that Dr. Raymond L. Benza, M.D., FACC, FAHA, FACP, USA, has joined the company’s Scientific Advisory Board (SAB). Dr. Benza is a global thought leader within pulmonary arterial hypertension (PAH) and has been working as an advisor to the company’s Phase II program with drug candidate CS1 in PAH.

Dr. Benza, M.D., FACC, FAHA, FACP, USA, comments, “Cereno Scientific’s CS1 has tremendous potential to be a game-changer for patients with PAH. I am pleased to have advised the company during 2020 and now look forward to joining the company’s SAB. These patients do not have effective treatment options today, which is why I feel it important to support the development of high-potential clinical drug candidates such as CS1.”

“Dr. Benza is a recognized global leader within the field of PAH treatment. His impressive experience with clinical studies in PAH has already yielded very valuable insights to our own understanding of the clinical and regulatory requirements of a PAH drug. Dr. Benza will add an important new perspective to the Cereno SAB as we advance our clinical development further,” says Sten R. Sörensen, CEO at Cereno Scientific.

Dr. Bertram Pitt, Chair of the SAB, notes, “I am pleased to welcome Dr. Benza to the Cereno Scientific Advisory Board. Dr. Benza is Head of Cardiology division at Ohio State University School of Medicine and is recognized as a leading expert in pulmonary hypertension. His expertise will broaden the board’s perspective and help us move more efficiently to develop the potential of CS1 and other new opportunities.”

Dr. Raymond L Benza is Professor of Medicine at The Ohio State University in Columbus, Ohio and an Adjunct Professor in the School of Biomedical Engineering at Carnegie Mellon University in Pittsburgh, PA. He is also the Bob and Corrine Frick Endowed Chair of Heart Failure at The Ohio State University Wexner Medical Center, Columbus, Ohio where he also serves as the Director of the Division of Cardiovascular Diseases. He is a fellow of the American College of Physicians, the American Heart Association Council on Clinical Cardiology, the American College of Chest Physicians and the American College of Cardiology. He is a diplomat of the American Board of Internal Medicine with certification in the subspecialties of cardiovascular diseases and advanced heart failure and transplantation. Dr. Benza currently holds a position on the Governance Committee at the International Society of Heart and Lung Transplantation and is the former treasurer of the society. He served on President Barack Obama’s Advisory Committee on Organ Transplantation (ACOT) in the Health Resources and Services Administration for 4 years and was knighted in 2015 by his Royal Highness Vittorio Emanuele of Italy for his philanthropic work in patients with pulmonary arterial hypertension. His primary clinical interests are the evaluation and treatment of advanced congestive heart failure, cardiac transplantation, and pulmonary arterial hypertension. He participates in major clinical studies of new therapies for the treatment of heart failure, mechanical support, and pulmonary hypertension. Dr. Benza is a funded investigator for the National Institutes of Health and the American Heart Association for his work in pulmonary arterial hypertension focusing on risk stratification, pharmacogenomics and new device therapies for this disease state.

For further information, please contact:

Daniel Brodén, CFO
Tel: +46 768 66 77 87
Email: info@cerenoscientific.com
www.cerenoscientific.com

About Cereno Scientific AB
Cereno Scientific is a leading clinical stage biotech company within cardiovascular epigenetic modulation. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. A clinical phase II study program for CS1 in PAH is expected to be initiated in mid-2021 under its US FDA granted orphan drug designation (ODD) status. In addition, Cereno has a preclinical HDAC inhibitor development program targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has an office in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.